Glisoxepide
![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
N-[2-(4-{[(Azepan-1-yl)carbamoyl]sulfamoyl}phenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide | |
Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.042.329 ![]() |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula
|
C20H27N5O5S |
Molar mass | 449.52388 g/mol |
Pharmacology | |
ATC code
|
A10BB11 (WHO) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
![]() ![]() ![]() | |
Infobox references | |
Glisoxepide (INN) is an orally available anti-diabetic drug from the group of sulfonylureas.[1] It belongs to second-generation sulfonylureas.[2]
References[]
- ^ Haupt E, Köberich W, Beyer J, Schöffling K (December 1971). "Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects". Diabetologia. 7 (6): 449–54. doi:10.1007/bf01212061. PMID 5004178.
- ^ Loubatières, A; Ribes, G; Mariani, MM; Alric, R (1973). "Pharmacological Comparison Between Tolbutamide and Two Second Generation Hypoglycemic Sulfonylureas (Glibenclamide and Glisoxepide)". Acta Diabetologica Latina. 10 (2): 261–82. doi:10.1007/bf02590661. PMID 4200420.
Categories:
- Potassium channel blockers
- Azepanes
- Carboxamides
- Isoxazoles
- Benzenesulfonylureas
- Gastrointestinal system drug stubs